Clinical Trial Update: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of surufatinib in combination with tislelizumab for advanced solid tumors has been terminated. Results were posted on 2025-05-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Colorectal Cancer
• Gastric Cancer
• Neuroendocrine Tumors
• Small Cell Lung Cancer
• Soft Tissue Sarcoma
• Solid Tumor

Drugs mentioned

• Surufatinib (Surufatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Hutchmed | Conditions: Metastatic Solid Tumor, Colorectal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-08